GSK plc (GLAXF) community

GLAXFOTCPharmaceutical PreparationsAlso trades as GSK

Financials through fiscal 2025, year ended Dec 31, 2025Score 9/30

$24.74+0.30 (+1.21%)

Close on Oct 19, 2026Market cap $106.83BP/E 13.3Yield –

Community

Notes and questions about GSK from other investors

No posts about GLAXF yet

Discussion is coming to every stock. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Where these numbers come from

Parsed from the XBRL in GSK's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-1.25 reverse split on Mar 10, 2023
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is GLAXF.

Compare: GLAXF vs MRK · GLAXF vs BMY · GLAXF vs PFE · GLAXF vs AZN · GLAXF vs VTRS

Revenue growth4.1% · median 4.4%

Gross margin72.4% · median 71.1%

Net margin17.5% · median 6.8%

Company	Revenue	Growth
MRK	$66.57B	+4.6%
PFE	$63.70B	-0.2%
BMY	$50.03B	+4.2%
GLAXF	£32.67B	+4.1%
AZN	$29.01B	+16.2%
VTRS	$14.74B	+4.4%

Company

Exchange: OTC
Industry: Pharmaceutical Preparations
Employees: 500,000
Auditor: Deloitte LLP
SEC CIK: 1131399

Advertisement
300 × 250